% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • system_architect_enterprise system_architect_enterprise Jan 30, 2013 7:30 AM Flag

    Lomitapide will outsell Kynamro 10-1 or higher

    The marketshare between Lomitapide and Kynamro will be heavily slanted towards Lomitapide given effectiveness, safety, and probability for success. I fully expect Lomitapide to outsell Kynamro overwhelmingly, especially once patients start taking both drugs and compare actual results.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I think exactly the opposite. Unless you have these juxta patients have their diet watched as closely as they had it watched in their study there is going to be a huge drop off in use. Xenical had over $850 million in sales in the second year. Last year sales of Xenical worldwide was only $50 million and that included sales from the OTC form of the drug.....which is a lower dies but still very bothersome forbthat diarrhea side effect. I think junta will have diarrhea side-effects like five fold that of Xenical. Also, the FDA is going to let a single armed 29 patient study suffice in the pediatric population. Unbelieveable that the fiimsy study for the adults made it through. Mr. Beer won't be able to fast talk that one, and expect a $70 million dollar bill to get even the most modest study through for that indication. t

2.21+0.02(+0.91%)Oct 21 4:00 PMEDT